Memory Pharmaceuticals, Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease

Oct. 15 , 2007 - Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced top-line data from the multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MEM 1003, a neuronal L-type calcium channel modulator, in Alzheimer's disease.The trial enrolled 183 subjects with mild to moderate Alzheimer's disease at over 40 centers in the United States and included monotherapy subjects and subjects on stable doses of cholinesterase inhibitors. The trial failed to meet its primary endpoint, which was a twelve-week mean change in the Alzheimer's disease Assessment Scale* -- Cognitive subscale (ADAS-cog) score in the overall population. ... Memory Pharmaceuticals' Press Release-